Search Result

Results for "

IL-17A inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Interleukin Related (41) Adenosine Deaminase (1) Androgen Receptor (1) Apoptosis (3) Aryl Hydrocarbon Receptor (1) Bacterial (1) Caspase (1) CXCR (1) Cytochrome P450 (1) DNA/RNA Synthesis (2) Epigenetic Reader Domain (1) Ferroptosis (1) FGFR (1) Fungal (1) G Protein-coupled Receptor Kinase (GRK) (1) Glutathione Peroxidase (2) Glutathione S-transferase (2) Histone Acetyltransferase (1) IFNAR (5) JAK (2) Keap1-Nrf2 (1) Lipoxygenase (1) Mitophagy (1) MMP (2) Necroptosis (1) NF-κB (3) NO Synthase (1) Notch (2) p38 MAPK (1) PARP (2) Phosphodiesterase (PDE) (1) PINK1/Parkin (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) ROR (4) SOD (2) STAT (3) TGF-beta/Smad (1) TNF Receptor (5) Toll-like Receptor (TLR) (1) VEGFR (1)
By Research Areas:	Cancer (12) Infection (3) Inflammation/Immunology (49) Metabolic Disease (4) Neurological Disease (3)

By Targets:

Interleukin Related (41)

Adenosine Deaminase (1)

Androgen Receptor (1)

Apoptosis (3)

Aryl Hydrocarbon Receptor (1)

Bacterial (1)

Caspase (1)

CXCR (1)

Cytochrome P450 (1)

DNA/RNA Synthesis (2)

Epigenetic Reader Domain (1)

Ferroptosis (1)

FGFR (1)

Fungal (1)

G Protein-coupled Receptor Kinase (GRK) (1)

Glutathione Peroxidase (2)

Glutathione S-transferase (2)

Histone Acetyltransferase (1)

IFNAR (5)

JAK (2)

Keap1-Nrf2 (1)

Lipoxygenase (1)

Mitophagy (1)

MMP (2)

Necroptosis (1)

NF-κB (3)

NO Synthase (1)

Notch (2)

p38 MAPK (1)

PARP (2)

Phosphodiesterase (PDE) (1)

PINK1/Parkin (1)

Pyroptosis (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (2)

ROR (4)

SOD (2)

STAT (3)

TGF-beta/Smad (1)

TNF Receptor (5)

Toll-like Receptor (TLR) (1)

VEGFR (1)

By Research Areas:

Cancer (12)

Infection (3)

Inflammation/Immunology (49)

Metabolic Disease (4)

Neurological Disease (3)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Targets Recommended: Interleukin Related IRAK Itk

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15826

SGC-CBP30 Maximum Cited Publications 20 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30, a chemical probe, is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

HY-139206

LY3509754 4 Publications Verification IL-17A inhibitor 1	Interleukin Related	Inflammation/Immunology
LY3509754 (IL-17A inhibitor 1) is a *IL-17A* inhibitor, with IC₅₀ values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells .

HY-177129

Simepdekinra LY4100511; DC-853	Interleukin Related	Inflammation/Immunology
Simepdekinra (LY4100511; DC-853) is an IL-17A antagonist. Simepdekinra can be used in the research of moderate to severe plaque-type psoriasis .

HY-P990222

Anti-Mouse/Rat IL-17A Antibody (17F3) 1 Publications Verification	Interleukin Related	Infection Metabolic Disease Inflammation/Immunology
Anti-Mouse/Rat IL-17A Antibody (17F3) is a mouse-derived IgG1κ type antibody inhibitor, targeting to mouse and rat *IL-17A. Anti-Mouse IL-17A* Antibody (17F3) can neutralize IL-17. Anti-Mouse/Rat IL-17A Antibody (17F3) can be used for the researches of infection, immunology and metabolic disease, such as M.intracellulare infection and diabetes .

HY-153780

Navepdekinra DC-806; LY4100504; S-011806	Interleukin Related	Inflammation/Immunology
Navepdekinra (DC-806) is an orally active, potent interleukin-17A (IL-17A) inhibitor (IC₅₀ = 10.81 nM). Navepdekinra disrupts the IL-17A protein-receptor interaction, suppressing the downstream pro-inflammatory signaling pathway. Navepdekinra inhibits arthritis in a collage-induced arthritis (CIA) rat model. Navepdekinra can be used for psoriasis, psoriatic arthritis, and ankylosing spondylitis .

HY-N3029

Noreugenin 2 Publications Verification	Interleukin Related Apoptosis Glutathione Peroxidase SOD Glutathione S-transferase Necroptosis	Inflammation/Immunology
Noreugenin is a phenolic compound found in Calea uniflora Less. Noreugenin inhibits myeloperoxidase activity and reduces levels of proinflammatory cytokines IL-1β and *IL-17A* levels in LPS (HY-D1056)-induced murine pleurisy model. Noreugenin reduces apoptosis and necrosis. Noreugenin reduces lipid peroxidation, and antioxidant enzyme (CAT, SOD, GST) activity. Noreugenin exhibits anti-inflammatory and antioxidant effects. Noreugenin can be used for the research of inflammatory conditions, such as pleurisy .

HY-139780

JNJ-61803534	ROR	Inflammation/Immunology
JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC₅₀ of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions .

HY-107390A

AX-024 hydrochloride 3 Publications Verification	TNF Receptor Interleukin Related IFNAR	Inflammation/Immunology Cancer
AX-024 hydrochloride is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC₅₀ ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and *IL-17A*.

HY-107390

AX-024 3 Publications Verification	TNF Receptor Interleukin Related IFNAR	Inflammation/Immunology Cancer
AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC₅₀ ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and *IL-17A*.

HY-P99335

Vunakizumab Anti-Human IL17A Recombinant Antibody; SHR-1314	Interleukin Related	Inflammation/Immunology
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis .

HY-P99515

Xeligekimab GR 1501	Interleukin Related	Inflammation/Immunology
Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade. Xeligekimab can be used for the research of inflammatory disease, such as radiographic axial spondyloarthritis .

HY-N0902

Dihydrosanguinarine 13,14-Dihydrosanguinarine	Fungal Bacterial Interleukin Related	Infection Inflammation/Immunology
Dihydrosanguinarine (13,14-Dihydrosanguinarine) is an alkaloid with antibacterial and anti-inflammatory activities, and also an important precursor of Sanguinarine (HY-N0052). Dihydrosanguinarine targets and regulates the TNF/IL-17/PI3K signaling pathway, downregulates the levels of pro-inflammatory factors such as *IL-17A, TNF-α* and IL-6, upregulates the expression of TGF-β, inhibits myeloperoxidase activity, and regulates the transcription of multiple inflammation-related genes. Dihydrosanguinarine exhibits antibacterial activity against a variety of oral microorganisms. Dihydrosanguinarine can be used in research related to liver inflammation and oral flora dysbiosis .

HY-145429

IL-17A modulator-2 2 Publications Verification	Interleukin Related	Neurological Disease Inflammation/Immunology Cancer
IL-17A modulator-2 is a *IL-17A* modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC₅₀ of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .

HY-139686

IL-17A inhibitor 2	Interleukin Related	Inflammation/Immunology
IL-17A inhibitor 2 is an *IL-17A* inhibitor for researching psoriasis, rheumatoid arthritis, and multiple sclerosis.

HY-155830

Morcamilast ME3183; PDE4-IN-14	Phosphodiesterase (PDE) Interleukin Related	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Morcamilast (ME3183) is a selective and orally active PDE4 inhibitor, with IC₅₀s of 1.28 nM (PDE4A1A), 2.33 nM (PDE4B1), and 1.63 nM (PDE4D2) respectively. Morcamilast shows weak inhibition of PDEs other than PDE4s Morcamilast is an anti-inflammatory agent and inhibits LPS (HY-D1056)-induced release of TNF-α, IL-12/23p40, IL-23, and *IL-17A* in human PBMCs and T cells. Morcamilast has antipruritic effect and can be used in the study of psoriasis, atopic dermatitis, and other inflammatory diseases .

HY-164826

Acetyl zingerone	Interleukin Related Reactive Oxygen Species (ROS) MMP Pyroptosis Ferroptosis Notch Keap1-Nrf2 PINK1/Parkin Mitophagy Caspase Apoptosis	Inflammation/Immunology Cancer
Acetyl zingerone is an analog of Zingerone (HY-14621). Acetyl zingerone downregulates the expression of ROS metabolism-related genes, fibroblast senescence-related genes, keratinocyte differentiation-related genes, and *IL-17A* target genes. Acetyl zingerone inhibits the activities of MMP-1, MMP-3, and MMP-12, as well as the activation of NLRP3 inflammasome, pyroptosis (pyroptosis), ferroptosis (ferroptosis), cartilage destruction, and UVA-induced cyclobutane pyrimidine dimer formation. Acetyl zingerone upregulates the expression of collagen, proteoglycan, extracellular matrix glycoprotein, Notch pathway, and GPX4 gene, activates Nrf2 and HO-1, induces extracellular matrix synthesis and PINK1/Parkin-mediated mitophagy (mitophagy), and promotes chondrocyte survival. Acetyl zingerone alleviates the progression of osteoarthritis in mice . Acetyl zingerone can be used in research related to skin aging, inflammatory skin diseases, osteoarthritis, melanoma, and non-melanoma skin cancer .

HY-148272

IL-17A modulator-3	Interleukin Related	Inflammation/Immunology Cancer
IL-17A modulator-3 (compound 253) is a *IL-17A* modulator. IL-17A modulator-3 inhibits IL-17A/A with an IC₅₀ value ＜10 μM. IL-17A modulator-3 can be used for the research of inflammation, cancer and autoimmune disease .

HY-145430

IL-17A modulator-1	Interleukin Related	Neurological Disease Inflammation/Immunology Cancer
IL-17A modulator-1 is a *IL-17A* modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC₅₀ of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .

HY-103637

Vimirogant VTP-43742	ROR	Inflammation/Immunology
Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor (K_i=3.5 nM; IC₅₀=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant has the potential for autoimmune disorders research .

HY-169306

IL-17A inhibitor 4	Interleukin Related	Inflammation/Immunology
IL-17A inhibitor 4 (Example 449) is a potent *IL-17A* inhibitor. IL-17A inhibitor 4 inhibits HTRF and NHK cells viability with IC₅₀s of 0.028 and 0.0047 μM, respectively .

HY-103637A

Vimirogant hydrochloride 1 Publications Verification VTP-43742 hydrochloride	ROR	Inflammation/Immunology
Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (K_i=3.5 nM; IC₅₀=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research .

HY-155244

12R-LOX-IN-2	Lipoxygenase DNA/RNA Synthesis	Inflammation/Immunology
12R-LOX-IN-2 (compound 7b) is an inhibitor of 12R-lipoxygenase (12R-LOX). 12R-LOX-IN-2 inhibits imiquimod (IMQ)-induced hyperproliferation of psoriatic keratinocytes and suppresses colony formation. 12R-LOX-IN-2 also reduced the protein level of Ki67 and the mRNA expression of IL-17A in IMQ-induced cells. 12R-LOX-IN-2 can be used in research into psoriasis and other skin-related inflammatory diseases .

HY-147128

PY109	Aryl Hydrocarbon Receptor Cytochrome P450 Interleukin Related	Inflammation/Immunology
PY109 is an orally active and highly selective aryl hydrocarbon receptor (AHR) agonist. PY109's EC₅₀ values in human-derived HepG2 and mouse Hepa-1c1c7 cells are 1.2 nM and 1.4 nM respectively. PY109 significantly upregulates the expression of CYP1A1 and IL-22, and inhibits the expression of IL-17A. PY109 significantly improves colitis in mice. PY109 can be used for research on colitis .

HY-172806

PARP14 inhibitor 1	PARP Interleukin Related	Inflammation/Immunology
PARP14 inhibitor 1 is an orally active, selective PARP14 inhibitor with an IC₅₀ of 5.52 nM. PARP14 inhibitor 1 exhibits favorable pharmacokinetic properties and in vivo safety. PARP14 inhibitor 1 enhances and stabilizes intracellular endogenous PARP14 protein levels, while effectively reducing the expression levels of IL-4, IL-13 and *IL-17A. PARP14 inhibitor* 1 can be used in research related to atopic dermatitis .

HY-P991091

COVA322	TNF Receptor Interleukin Related	Inflammation/Immunology
COVA322 is a bispecific TNF and *IL-17A* antibody. COVA322 inhibits simultaneously TNF and the IL-17A homodimer that can be used for the study of inflammatory diseases .

HY-178714

JNJ627	Interleukin Related	Inflammation/Immunology
JNJ627 is a small molecule allosteric inhibitor of *IL-17A* with a K_D of 92 nM. JNJ627 effectively inhibits the binding of IL-17A and IL-17RA, with an IC₅₀ value of 16 nM. JNJ627 is capable of inhibiting the secretion of G-CSF (granulocyte colony-stimulating factor) caused by IL-17A stimulation. JNJ627 can be used for the study of autoimmune diseases (such as psoriasis) .

HY-158159

IL17A-IN-1	Interleukin Related	Inflammation/Immunology Cancer
IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .

HY-162490

TF-S14	ROR	Inflammation/Immunology
TF-S14 is a reverse agonist of RORγt. TF-S14 reduces Th17 cell-associated cytokine production, including IL-17A, IL-21, and IL-22 by binding to and inhibiting RORγt activity. TF-S14 can be used in the study of autoimmune diseases and rejection in allotransplantation .

HY-168971

Paeoniflorin-6′-O-benzene sulfonate CP-25	IFNAR STAT TNF Receptor Interleukin Related CXCR JAK G Protein-coupled Receptor Kinase (GRK)	Inflammation/Immunology
Paeoniflorin-6′-O-benzene sulfonate (CP-25) is the inhibitor for G protein-coupled receptor kinase 2 (GRK2) that inhibits the translocation of GRK2 to the cell membrane, inhibits JAK1/STAT3 signaling pathway. Paeoniflorin-6′-O-benzene sulfonate inhibits IL-17A/CXCL2-induced proliferation of HaCaT. Paeoniflorin-6′-O-benzene sulfonate reduces the levels of inflammatory factors and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3 and CXCL9, alleviates Imiquimod (HY-B0180)-induced psoriasis in mouse model .

HY-P991260

CNTO-6785	Interleukin Related	Infection
CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .

HY-P991263

SCH-900117	Interleukin Related	Inflammation/Immunology
SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .

HY-179113

IL-17A-IN-5	Interleukin Related	Inflammation/Immunology
IL-17A-IN-5 (Compound 9) is an orally active *IL-17A* inhibitor. IL-17A-IN-5 demonstrates a clear dose-dependent inhibition of arthritis .

HY-P991595

HB-0017	Interleukin Related	Inflammation/Immunology
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting *IL-17A. HB-0017 inhibits* the IL-6 secretion induced by IL-17A with an IC₅₀ of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-153276

Androgen receptor-IN-5	Androgen Receptor	Cancer
Androgen receptor-IN-5 is an androgen receptor inhibitor with potent anticancer effects. Androgen receptor-IN-5 also inhibits the production of IL-17A, IL- 17F and INF-γ (WO2023281097A1,Example 1/1) .

HY-P991261

CJM-112	Interleukin Related	Inflammation/Immunology
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .

HY-170611

IL-17-IN-3	Interleukin Related	Inflammation/Immunology
IL-17-IN-3 (compound 11) is an IL-17A inhibitor with an IC₅₀ value of 35 nM. IL-17-IN-3 exhibits no adverse effects in a rat tolerability study after a four-day administration of up to 300 mg/kg/day .

HY-168084

IL-17-IN-1	Interleukin Related	Inflammation/Immunology
IL-17-IN-1 (26) is an orally active IL-17 inhibitor, with IC₅₀ values of 0.013 μM and 0.004 μM for IL-17A and IL-6 release, respectively. IL-17-IN-1 (26) effectively reduces knee swelling in a rat arthritis model .

HY-169007

STAT3-IN-34	STAT	Inflammation/Immunology
STAT3-IN-34 (Compound 15E) is an inhibitor for STAT3, and inhibits the nuclear translocation and transcriptional regulator activity of STAT3. STAT3-IN-34 inhibits the proliferation of cell HaCaT with IC₅₀ of 0.008 μM. STAT3-IN-34 inhibits IL-17A expression and ameliorates Imiquimod (HY-B0180)-induced psoriasis in mice .

HY-N11768

4-Methoxylonchocarpin	NF-κB Interleukin Related Toll-like Receptor (TLR)	Inflammation/Immunology
4-Methoxylonchocarpin is an orally active anti-inflammatory agent. 4-methoxylonchocarpin inhibits the binding of LPS to Toll-like Receptor (TLR) TLR4 to inhibit NF-κB activation and TNF Receptor and IL-6 expression. 4-Methoxylonchocarpin also inhibits the phosphorylation of TGF-beta activated kinase 1 and TNBS-induced expression of IL-1β, IL-17A, and TNF. 4-methoxylonchocarpin can improve 2,4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis mouse model .

HY-155243

12R-LOX-IN-1	DNA/RNA Synthesis	Inflammation/Immunology
12R-LOX-IN-1 (Compound 4a) is a 12R-LOX inhibitor (IC₅₀: 28.25 μM). 12R-LOX-IN-1 inhibits the hyper-proliferative state and colony forming potential of Imiquimod (HY-B0180)-induced psoriatic keratinocytes. 12R-LOX-IN-1 inhibits reactive oxygen species, Ki67, IL-17A, TNF-α and IL-6 production. 12R-LOX-IN-1 can be used for antipsoriatic research .

HY-N3029R

Noreugenin (Standard)	Reference Standards Interleukin Related Apoptosis Glutathione Peroxidase SOD Glutathione S-transferase	Inflammation/Immunology
Noreugenin (Standard) is the analytical standard of Noreugenin. This product is intended for research and analytical applications. Noreugenin is a phenolic compound found in Calea uniflora Less. Noreugenin inhibits myeloperoxidase activity and reduces levels of proinflammatory cytokines IL-1β and *IL-17A* levels in LPS (HY-D1056)-induced murine pleurisy model. Noreugenin reduces apoptosis and necrosis. Noreugenin reduces lipid peroxidation, and antioxidant enzyme (CAT, SOD, GST) activity. Noreugenin exhibits anti-inflammatory and antioxidant effects. Noreugenin can be used for the research of inflammatory conditions, such as pleurisy .

HY-P990252

Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2)	Notch Interleukin Related NF-κB VEGFR FGFR NO Synthase	Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and *IL-17A* production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma .

HY-N12481

Cephalandole B	Others	Inflammation/Immunology
Cephalandole B is an indigo alkaloid that has the activity of inhibiting IL-17A gene expression. Cephalandole B significantly inhibited the activity of IL-17A luciferase reporter gene in Jukat cells, and this inhibitory effect was dose-dependent. Cephalandole B may have important application prospects in inflammation-related research .

HY-181827

IL-17-IN-7	Interleukin Related	Inflammation/Immunology
IL-17-IN-7 (Compound 23) is a IL-17 inhibitor with a pIC₅₀ of 7.1 against *IL-17A* .

HY-181826

IL-17-IN-6	Interleukin Related	Inflammation/Immunology
IL-17-IN-6 is a IL-17 inhibitor with a pIC₅₀ of 7.6 against human targets. IL-17-IN-6 binds to *IL-17A* and blocks downstream pro-inflammatory signaling pathways. IL-17-IN-6 inhibits the release of IL-6 from normal human skin fibroblasts stimulated by *IL-17A* and TNF. IL-17-IN-6 can be used for research on inflammatory and autoimmune diseases .

HY-180608

TCR-IN-1	Interleukin Related IFNAR	Inflammation/Immunology
TCR-IN-1 (Compound A-33) is a TCR inhibitor. TCR-IN-1 blocks cytokine (IL-2, TNFα, IFNγ, *IL-17A*) release .

HY-N8529

Eupalestin	NF-κB p38 MAPK Adenosine Deaminase Interleukin Related	Inflammation/Immunology
Eupalestin is an anti-inflammatory agent. Eupalestin reduces the levels of p-p65 NF-κB and p-p38 MAPK. Eupalestin inhibits MPO and adenosine deaminase. Eupalestin decreases the levels of pro-inflammatory cytokines including *IL-17A, IL-6, TNF* and IFN-γ. Eupalestin exerts anti-inflammatory activity in a carrageenan (HY-125474)-induced mouse pleurisy model .

HY-107390AR

AX-024 hydrochloride (Standard)	Reference Standards TNF Receptor Interleukin Related IFNAR	Inflammation/Immunology Cancer
AX-024 hydrochloride (Standard) is the analytical standard of AX-024 (hydrochloride) (HY-107390A). This product is intended for research and analytical applications. AX-024 hydrochloride is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC₅₀ ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.

HY-183548

XW-17	PARP	Inflammation/Immunology
XW-17 is a PARP14 inhibitor with an IC₅₀ of 3.03 nM and selectivity over other PARP family members.XW-17 suppresses PARP14-mediated mono-ADP-ribosylation, engages and stabilizes endogenous PARP14 protein.XW-17 attenuates skin lesions and decreases expression of IL-4, IL-13, IgE, and IL-17A in an atopic dermatitis-like mouse model.XW-17 can be used for the research of atopic dermatitis .

HY-183370

JAK2/STAT3-IN-2	JAK STAT Interleukin Related	Inflammation/Immunology
JAK2/STAT3-IN-2 is an orally active JAK2/STAT3 inhibitor. JAK2/STAT3-IN-2 inhibits the phosphorylation of tyrosine residues in JAK2 and STAT3, blocks downstream signal transduction, disrupts the dimerization and nuclear translocation of STAT3, and suppresses pro-inflammatory transcriptional activity. JAK2/STAT3-IN-2 inhibits the expression of *IL-17A* and IL-17F, reduces immune cell infiltration, and inhibits the production of NO simultaneously. JAK2/STAT3-IN-2 exerts a protective effect in a mouse model of ulcerative colitis induced by DSS (HY-116282C). JAK2/STAT3-IN-2 can be used for the research of ulcerative colitis .

Cat. No.	Product Name	Target	Research Area	Image